Table 3.

Multivariable Cox proportional hazards regression analyses on disease-free survival for estrogen receptor (ER)-positive and -negative cohorts

Cohort	Hazard ratio (95% CI)	Pvalue
ER-positive cohort (n = 851)
CMF versus goserelin	1.00 (0.74–1.36)	0.99
CMF→goserelin versus goserelin	0.71 (0.51–1.00)	0.05
CMF→goserelin versus CMF	0.72 (0.51–1.00)	0.05
Age <40 versus ≥40	1.50 (1.10–2.06)	0.01
Primary surgical treatment		0.0002
BCS without RT versus Mast	2.39 (1.45–3.94)
BCS with RT versus Mast	0.83 (0.63–1.11)
Tumor size (cm)		0.19
1.1–2.0 versus ≤1	1.14 (0.73–1.79)
>2.1 versus ≤1	1.43 (0.90–2.27)
Grade		0.0001
2 versus 1	1.75 (1.14–2.70)
3 versus 1	2.54 (1.63–3.97)
ER-negative cohort (n = 205)
CMF versus goserelin	0.81 (0.46–1.42)	0.46
CMF→goserelin versus goserelin	0.71 (0.40–1.24)	0.23
CMF→goserelin versus CMF	0.87 (0.49–1.55)	0.64
Age <40 versus ≥40	0.95 (0.56–1.61)	0.84
Primary surgical treatment		0.69
BCS without RT versus Mast	1.46 (0.61–3.52)
BCS with RT versus Mast	1.04 (0.63–1.73)
Tumor size (cm)		0.31
1.1–2.0 versus ≤1	0.55 (0.26–1.19)
>2.1 versus ≤1	0.63 (0.29–1.38)
Grade		0.24
2 versus 1	1.32 (0.30–5.72)
3 versus 1	0.82 (0.20–3.39)

CMF, cyclophosphamide, methotrexate and fluorouracil; CI, confidence interval; RT, radiation therapy; BCS, breast-conserving surgery; Mast, mastectomy.